Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robin Vann

Ophthalmology Durham, NC Medical Doctor

NPI 1679660054 CMS profile 866366

3802 Erwin Road Wadsworth Bldg, Duke Eye Center, Durham, NC 27710

Open in the dashboard

General payments

$212,628

252 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robin Vann of Durham, NC is reported in the CMS Open Payments database as having received $212,628 across 252 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $41,557 39
2024 General $33,303 34
2023 General $22,142 30
2022 General $25,576 28
2021 General $27,873 33
2020 General $21,698 24
2019 General $40,480 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robin Vann
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Robin Vann were reported at $41,557. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Robin Vann Ophthalmology median Middle half National median
2019 $40,480 $258 $104–$655 $163
2020 $21,698 $126 $45–$321 $114
2021 $27,873 $205 $76–$534 $132
2022 $25,576 $266 $100–$678 $149
2023 $22,142 $308 $117–$745 $160
2024 $33,303 $340 $127–$846 $164
2025 $41,557 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $131,537 179 payments
  2. Alcon Research LLC $77,510 58 payments
  3. Ocular Therapeutix, Inc. $3,263 11 payments
  4. Quidel Corporation $214 1 payment
  5. Bausch & Lomb Americas Inc. $39 1 payment
  6. Carl Zeiss Meditec, Inc. $36 1 payment
  7. TearLab Corp $31 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $188,596 133 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,920 4 payments
  3. Food and Beverage $7,309 90 payments
  4. Travel and Lodging $6,502 24 payments
  5. Gift $302 1 payment
Products named General payments · program years 2019–2025
  1. ARGOS $23,524 25 payments
  2. Verion $13,230 7 payments
  3. Clareon $9,607 11 payments
  4. ORA $8,645 12 payments
  5. Capella Aberrometer $8,330 11 payments
  6. AcrySof IQ VIVITY $7,995 9 payments
  7. LenSx $7,246 8 payments
  8. AcrySof IQ PanOptix UV IOL $6,268 10 payments
  9. AcrySof $3,865 9 payments
  10. AcrySof IQ PanOptix $3,750 2 payments
  11. Other $24,418 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

102

Median for Ophthalmology: 891

Drug cost

$2,086

Median for Ophthalmology: $68,233

Branded share of claims

11.8%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 26 $794
Ketorolac Tromethamine Generic 30 $490
Valacyclovir Valacyclovir Hcl Brand 12 $459
Ofloxacin Generic 23 $243
Latanoprost Generic 11 $100

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$222,601

Medicare's payments for the services billed

Medicare patients

423

Average age 75

Services billed

1,453

267 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 45%
Ischemic heart disease 24%
Diabetes 22%
Osteoporosis 22%
Chronic kidney disease 19%
Cancer 18%
Depression 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

252 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record